APA

Moore M., Gill S., Asmis T., Berry S., Burkes R., Zbuk K., Alcindor T., Jeyakumar A., Chan T., Rao S., Spratlin J., Tang P. A., Rothenstein J., Chan E., Bendell J., Kudrik F., Kauh J., Tang S., Gao L., Kambhampati S. R. P., Nasroulah F., Yang L., Ramdas N., Binder P. & Strevel E. (20171226). Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K, Alcindor T, Jeyakumar A, Chan T, Rao S, Spratlin J, Tang P A, Rothenstein J, Chan E, Bendell J, Kudrik F, Kauh J, Tang S, Gao L, Kambhampati S R P, Nasroulah F, Yang L, Ramdas N, Binder P and Strevel E. 20171226. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Moore M., Gill S., Asmis T., Berry S., Burkes R., Zbuk K., Alcindor T., Jeyakumar A., Chan T., Rao S., Spratlin J., Tang P. A., Rothenstein J., Chan E., Bendell J., Kudrik F., Kauh J., Tang S., Gao L., Kambhampati S. R. P., Nasroulah F., Yang L., Ramdas N., Binder P. and Strevel E. (20171226). Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K, Alcindor T, Jeyakumar A, Chan T, Rao S, Spratlin J, Tang P A, Rothenstein J, Chan E, Bendell J, Kudrik F, Kauh J, Tang S, Gao L, Kambhampati S R P, Nasroulah F, Yang L, Ramdas N, Binder P and Strevel E. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. : Annals of oncology : official journal of the European Society for Medical Oncology. 20171226.